Cells within the intestines perform various roles including nutrient absorption, sensing, and maintaining homeostasis. Certain chronic disorders are distinctly characterized by gut inflammation, which disrupts intestinal cells and can lead to a remodeling of the gut and the introduction of new immune cells. To better understand the types of cells and their positioning within the intestines, researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, in collaboration with investigators at Boston Children’s Hospital, used a new technique known as MERFISH (multiplexed-error robust-fluorescence in situ hybridization) to analyze 940 genes in 1.35 million intestinal cells in a mouse model of colitis. They identified cell populations associated with healthy and inflamed states, mapped their spatial neighborhoods, and traced the evolution of these populations during the inflammation process. One significant cell type to note was fibroblasts, that, when in a distressed state, can induce inflammation associated fibroblasts (IAFs), which may help remodel extracellular matrixes, recruit immune cells, and produce inflammatory cytokines.
However, some key questions still remain, including the specific diversity of IAF populations, their precise tissue locations, and how they emerge during inflammation. Nevertheless, the researchers were able to generate a unique spatial atlas of a mouse colon both in a healthy state, and during intestinal inflammation, which has the potential to assist with therapeutic treatments for chronic inflammatory diseases. In previous studies, IAFs have been observed in a variety of diseases, including cancers and autoimmune diseases, so understanding the role and mechanisms of IAFs may help with the development of treatments for these other diseases.
“Our team wanted to better understand how cells are organized within the gut, and how inflammation can impact cellular interactions and communication at the tissue scale,” said senior author Roni Nowarski, PhD, of the Brigham’s Department of Neurology and Harvard Medical School’s Department of Immunology. “This work is particularly exciting and has given us a better understanding of the tissue context of cellular responses during inflammation, which we hope will help us design better therapeutics to fight serious chronic inflammatory diseases.”
The full article can be read in Cell.
Authorship: Co-authors of the paper include Paolo Cadinu, Kisha N. Sivanathan, Aditya Misra, Rosalind J. Xu,Davide Mangani, Evan Yang, JosephM. Rone, Katherine Tooley, YoonChul Kye, Lloyd Bod, Ludwig Geistlinger, Tyrone Lee, Noriaki Ono, Gang Wang, Liliana Sanmarco, Francisco J. Quintana, Ana C. Anderson, Vijay K. Kuchroo. Co-senior authors are Jeffrey R. Moffitt and Roni Nowarski.
Paper cited: Cadinu, P et al. “Charting the cellular biogeography in colitis reveals fibroblast trajectories and coordinated spatial remodeling”. Cell. DOI: 10.1101/2023.05.08.539701.
Journal
Cell
Method of Research
Experimental study
Subject of Research
Cells
Article Title
Charting the cellular biogeography in colitis reveals fibroblast trajectories and coordinated spatial remodeling
Article Publication Date
2-Apr-2024
COI Statement
J.R.M is a co-founder of, stake-holder in, and advisor for Vizgen, Inc. J.R.M. is an inventor on patents associated with MERFISH applied for on his behalf by Harvard University and Boston Children’s Hospital. J.R.M.’s interests were reviewed and are managed by Boston Children’s Hospital in accordance with their conflict-of-interest policies. R.N. is a paid consultant for Quris-AI. V.K.K. has an ownership interest in Tizona Therapeutics, Trishula Therapeutics, Celsius Therapeutics, Bicara Therapeutics, Larkspur Therapeutics. V.K.K. has financial interests in Biocon Biologic, Compass, Elpiscience Biopharmaceutical Ltd, Equilium Inc, PerkinElmer, and Syngene Intl. V.K.K. is a member of SABs for Cell Signaling Technology, Elpiscience Biopharmaceutical Ltd, GlaxoSmithKline, Larkspur, Novartis Sabatolimab, Tizona Therapeutics, Tr1X and Werewolf. A.C.A. is a member of the SAB for Tizona Therapeutics, Trishula Therapeutics, Compass Therapeutics, Zumutor Biologics, ImmuneOncia, and Nekonal Sarl. A.C.A. is also a paid consultant for iTeos Therapeutics, Larkspur Biosciences, and Excepgen. R.N., V.K.K., and A.C.A.’s interests were reviewed and managed by Mass General Brigham in accordance with their conflict-of-interest policies. Additional authors in this manuscript declare no competing financial interests.